GlassScriptPhysician profile
Hung Min Sung
NPI 1063692150
$14,391.04
in general payments reported to CMS, 2019-2025
42 companies · $250 in 2025
The $250 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,185 · 2020: $1,419 · 2021: $2,249 · 2022: $3,267 · 2023: $3,009 · 2024: $3,011 · 2025: $250.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,271.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,270.51 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $4,236.80 | 2019-2024 | Farxiga, Breztri, Airsupra |
| Amgen INC. | $1,163.30 | 2019-2023 | Otezla, Repatha, Evenity |
| Glaxosmithkline, LLC. | $1,097.08 | 2019-2024 | Arexvy, Trelegy Ellipta |
| Lilly USA, LLC | $987.41 | 2019-2024 | Mounjaro, Trulicity, Jardiance |
| Boehringer Ingelheim Pharmaceuticals, INC. | $826.44 | 2020-2024 | Jardiance |
| Abbvie INC. | $719.64 | 2020-2024 | Linzess, Viberzi |
| Nestle Healthcare Nutrition INC. | $400.72 | 2021-2022 | |
| Corcept Therapeutics | $337.68 | 2023-2024 | Korlym |
| Janssen Pharmaceuticals, INC | $306.68 | 2019-2022 | |
| Allergan, INC. | $285.50 | 2020 | |
| Novartis Pharmaceuticals Corporation | $276.62 | 2019-2022 | |
| Gilead Sciences, INC. | $275.00 | 2024 | Epclusa, Vemlidy |
| Xeris Pharmaceuticals, INC. | $258.28 | 2023 | Gvoke Hypopen, Recorlev |
| Ibsa Pharma INC. | $250.00 | 2022-2023 | Tirosint |
| Ardelyx, INC. | $250.00 | 2024-2025 | Ibsrela |
Show all 42 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Phathom Pharmaceuticals, INC. | $238.28 | 2024 | Voquezna |
| Novo Nordisk INC | $227.37 | 2019-2024 | Ozempic, Rybelsus |
| Takeda Pharmaceuticals U.S.A., INC. | $223.94 | 2020-2021 | |
| Pfizer INC. | $218.61 | 2019-2021 | |
| Ironwood Pharmaceuticals, INC | $194.33 | 2020-2024 | Linzess |
| Stryker Corporation | $149.97 | 2022 | |
| Cequr Corporation | $142.66 | 2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $142.54 | 2021-2024 | |
| Otsuka America Pharmaceutical, INC. | $131.36 | 2024 | Rexulti |
| Vanda Pharmaceuticals INC. | $125.00 | 2025 | Fanapt |
| Dexcom, INC. | $120.54 | 2023 | Dexcom G7 Gss (161) |
| Impel Pharmaceuticals INC. | $114.99 | 2022 | |
| Fidia Pharma USA INC. | $89.52 | 2020-2023 | Hymovis, Triluron |
| E.R. Squibb & Sons, L.L.C. | $77.89 | 2020-2022 | |
| Sanofi-Aventis U.S. LLC | $76.10 | 2020-2021 | |
| Kowa Pharmaceuticals America, INC. | $65.11 | 2020-2021 | |
| Amarin Pharma, INC. | $64.08 | 2019-2020 | |
| Avanos Medical | $62.73 | 2024 | Trivisc Sodium Hyaluronate |
| Astellas Pharma US INC | $61.46 | 2024 | Veozah |
| Merck Sharp & Dohme LLC | $49.74 | 2019-2024 | Gardasil 9, Gardasil, Capvaxive |
| Exact Sciences Corporation | $36.48 | 2023-2024 | Cologuard Collection Kit |
| Organon LLC | $30.00 | 2023 | Nexplanon |
| Depuy Synthes Sales INC. | $21.17 | 2019 | |
| Biohaven Pharmaceuticals, INC. | $16.76 | 2021 | |
| Ferring Pharmaceuticals INC. | $14.68 | 2019 | |
| Cumberland Pharmaceuticals, INC. | $13.10 | 2022 | |
| Arbor Pharmaceuticals, INC. | $11.48 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Hung Sung listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.